Literature DB >> 15539003

Chronic inflammatory demyelinating polyradiculoneuropathy in diabetes mellitus.

D Ram Ayyar1, Khema R Sharma.   

Abstract

There is a higher incidence of demyelinating peripheral neuropathy responsive to immunomodulating treatment in patients with diabetes mellitus. The diagnosis is often overlooked and the patients are given the label of "diabetic neuropathy." Progressive symmetric or asymmetric motor deficit, progressive sensory neuropathy in spite of optimal diabetic control, and unusually high cerebrospinal fluid protein level in "diabetic neuropathy" should alert the clinician to the possibility of an underlying treatable demyelinating peripheral neuropathy masquerading as "diabetic neuropathy."

Entities:  

Mesh:

Year:  2004        PMID: 15539003     DOI: 10.1007/s11892-004-0048-y

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  29 in total

Review 1.  Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force.

Authors: 
Journal:  Neurology       Date:  1991-05       Impact factor: 9.910

Review 2.  The effects of intravenous immune globulin on complement-dependent immune damage of cells and tissues.

Authors:  M M Frank; M Basta; L F Fries
Journal:  Clin Immunol Immunopathol       Date:  1992-01

3.  Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy.

Authors:  K C Gorson; G Allam; A H Ropper
Journal:  Neurology       Date:  1997-02       Impact factor: 9.910

4.  [Incidence of diabetic neuropathy which fulfills electrophysiologic criteria of CIDP].

Authors:  H Miyasaki; O Hasegawa; I Mori; S Matsumoto; T Arita
Journal:  No To Shinkei       Date:  1999-05

5.  CMAP variation over a length of nerve in diabetic neuropathy.

Authors:  A M Tjon-a-Tsien; H H Lemkes; P M Callenbach; J G Van Dijk
Journal:  Muscle Nerve       Date:  1995-08       Impact factor: 3.217

6.  Anti-ganglioside GM1 antibody and distal symmetric "diabetic polyneuropathy" with dominant motor features.

Authors:  Z Milicevic; P G Newlon; G L Pittenger; K B Stansberry; A I Vinik
Journal:  Diabetologia       Date:  1997-11       Impact factor: 10.122

7.  An investigation of antibodies to nerve growth factor in diabetic autonomic neuropathy.

Authors:  M M Zanone; J P Banga; M Peakman; M Edmonds; P J Watkins
Journal:  Diabet Med       Date:  1994-05       Impact factor: 4.359

8.  Human immunoglobulin preparations for intravenous use prevent experimental autoimmune uveoretinitis.

Authors:  A Saoudi; V Hurez; Y de Kozak; J Kuhn; S V Kaveri; M D Kazatchkine; P Druet; B Bellon
Journal:  Int Immunol       Date:  1993-12       Impact factor: 4.823

9.  Diabetic peripheral neuropathy: a clinicopathologic and immunohistochemical analysis of sural nerve biopsies.

Authors:  D S Younger; G Rosoklija; A P Hays; W Trojaborg; N Latov
Journal:  Muscle Nerve       Date:  1996-06       Impact factor: 3.217

Review 10.  Human IgG Fc receptors.

Authors:  C L Anderson
Journal:  Clin Immunol Immunopathol       Date:  1989-11
View more
  3 in total

Review 1.  Diabetic Microvascular Disease: An Endocrine Society Scientific Statement.

Authors:  Eugene J Barrett; Zhenqi Liu; Mogher Khamaisi; George L King; Ronald Klein; Barbara E K Klein; Timothy M Hughes; Suzanne Craft; Barry I Freedman; Donald W Bowden; Aaron I Vinik; Carolina M Casellini
Journal:  J Clin Endocrinol Metab       Date:  2017-12-01       Impact factor: 5.958

Review 2.  Chronic Inflammatory Demyelinating Polyradiculoneuropathy in Association With Concomitant Diseases: Identification and Management.

Authors:  Yan Chen; Xiangqi Tang
Journal:  Front Immunol       Date:  2022-07-04       Impact factor: 8.786

3.  Temporal Dispersion and Duration of the Distal Compound Muscle Action Potential Do Not Distinguish Diabetic Sensorimotor Polyneuropathy From Chronic Inflammatory Demyelinating Polyneuropathy.

Authors:  Monica Alcantara; Mylan Ngo; James de la Cruz; Deepak Menon; Carolina Barnett-Tapia; Hans Katzberg; Vera Bril
Journal:  Front Neurol       Date:  2022-04-26       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.